View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
April 10, 2019updated 12 Jul 2022 1:06pm

NanOlogy starts enrolment in NanoDoce’s Phase I/II trial

US-based NanOlogy has commenced patient enrolment in the Phase I/II clinical trial evaluating its NanoDoce injection in bladder cancer.

US-based NanOlogy has commenced patient enrolment in the Phase I/II clinical trial evaluating its NanoDoce injection in bladder cancer.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NanoDoce is a sterile submicron particle suspension of docetaxel. The therapeutic is stable in powder form and is suspended before use. It is designed for direct delivery to the diseases site.

The Phase I/II trial is intended to study the safety and preliminary efficacy of NanoDoce in around 75 patients with high-risk non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC).

“The local delivery of submicron particle docetaxel suspension (NanoDoce) represents an important step in evaluating new therapies.”

Participants will undergo transurethral bladder tumour resection, followed by direct injection of NanoDoce into the index tumour resection site base in conjunction with an intravesical instillation of the therapeutic.

NMIBC patients will receive additional intravesical instillations, while those with MIBC will follow institutional standard of care.

The primary outcome of the trial is the incidence of treatment-emergent adverse events, while secondary outcome measures include pharmacokinetics and tumour recurrence.

Trial principal investigator Donald Lamm said: “The local delivery of submicron particle docetaxel suspension (NanoDoce) represents an important step in evaluating new therapies for the treatment of bladder cancer.

“If this investigational drug can be proven to delay or prevent disease progression and need for cystectomy, it would contribute significantly to the quality of life of patients with this disease.”

According to preclinical findings, submicron particle technology boosts drug penetration into the bladder wall and improves the duration of activity.

In one of the preclinical studies using a xenograft animal model, NanoDoce intratumoral injection demonstrated long-lasting, high drug concentration in tumour tissue, significant tumour regression and immune cell infiltration.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena